Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.

ABSTRACT:

Background

Bile acid metabolism is altered in multiple sclerosis (MS) and tauroursodeoxycholic acid (TUDCA) supplementation ameliorated disease in mouse models of MS.

Methods

Global metabolomics was performed in an observational cohort of people with MS followed by pathway analysis to examine relationships between baseline metabolite levels and subsequent brain and retinal atrophy. A double-blind, placebo-controlled trial, was completed in people with progressive MS (PMS), randomized to receive either TUDCA (2g daily) or placebo for 16 weeks. Participants were followed with serial clinical and laboratory assessments. Primary outcomes were safety and tolerability of TUDCA, and exploratory outcomes included changes in clinical, laboratory and gut microbiome parameters.

Resu

SUBMITTER: Ladakis DC 

PROVIDER: S-EPMC10827276 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature